Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.

NCT02047110 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02047110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02047110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
January 28, 2014
Completion date
July 25, 2016
Enrollment
159 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis (as)